Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Clinicopathologic Conference, Posterior Reversible Encephalopathy Syndrome Due to Sickle Cell Disease
NEJM 392:268-276, Case 2-2025, 2025
Prevalence of Venous Infarction in Patients with Cerebral Venous Thrombosis:Baseline Diffusion-Weighted MRI and Follow-Up MRI
Stroke 54:1808-1814, Alajmi.E.,et al, 2023
Alzheimers Disease
Lancet 397:1577-1590, Scheltens, P.,et al, 2021
Clinicopathologic Conference, Glioblastonoma, WHO grade IV of IV, with Methylation of the MGMT Promoter
NEJM 366:2112-2120, Case 17-2012, 2012